Use of Cetuximab in Combination with Cisplatin and Adjuvant Pelvic Radiation for Stage IIIB Vulvar Carcinoma.

摘要: Vulvar cancer is a rare carcinoma constituting only 4% of gynecologic malignancies and 0.6% female cancers. Most chemotherapy regimens have been created from extrapolation anal cervical research. Advanced stages the worst prognosis oftentimes invasive surgical procedures are needed to cure disease with high recurrence rates. Case. A 50 yo G2P2 presented for 2 cm mass in her right labia. The patient underwent partial radical vulvectomy bilateral superficial deep inguinal lymph node dissection. Bilateral nodes were positive residual disease. whole pelvic radiation cisplatin as radiosensitizer. primary tumor was epidermal growth factor receptor (EGFR) cetuximab, monoclonal antibody EGFR, added. seven cycles including cetuximab adjuvant therapy pelvis. She currently without evidence since completing treatment 4 years ago. Conclusion. One previous case report showed short-term palliative success five months recurrent, metastatic vulvar cancer. This suggests that could possibly be used initial management patients advanced improve prognosis.